沃森生物：目前公司共有8个自主疫苗产品正式上市销售

Core Viewpoint - Watson Bio has launched a total of 8 self-developed vaccine products (14 specifications) for sale, focusing on preventing diseases caused by specific pathogens [1] Group 1: Vaccine Products - The company offers the following vaccines: 13-valent pneumonia conjugate vaccine (both vial and pre-filled types), bivalent HPV vaccine (both vial and pre-filled types), 23-valent pneumonia polysaccharide vaccine (both vial and pre-filled types), type b Haemophilus influenzae conjugate vaccine (both vial and pre-filled types), A and C group meningococcal polysaccharide conjugate vaccine (both vial and pre-filled types), ACYW135 group meningococcal polysaccharide vaccine (both vial and pre-filled types), A and C group meningococcal polysaccharide vaccine (vial type), and adsorbed acellular DTP combined vaccine (vial type) [1] Group 2: Marketing and Strategy - The company aims to strengthen product marketing efforts by developing practical strategies and execution measures, enhancing talent development, and leveraging scientific outreach to boost confidence and implementation [1] - The focus will be on improving the coverage and penetration rates of terminal channels to create value for the company and its shareholders [1]